Siemens Medical Solutions USA, Inc.

Molecular Technologies, Inc.

Eli Lilly and Company

Threshold Pharmaceuticals, Inc.

Henry Clifton Padgett

Joseph C Walsh

Hartmuth C Kolb

Qianwa Liang

Umesh B Gangadharmath

Farhad Karimi

Tieming Zhao

Kai Chen

Dhanalakshmi Kasi

Brian A Duclos

Zhiyong Gao

Vani P Mocharla

Thomas Lee Collier

Wei Zhang

Gang Chen

Peter J H Scott

Chunfang Xia

Bing Wang

Tanea Ysaguirre

Eric Wang

Anjana Sinha

Robert M Yeh

Peter Jh Scott

Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.

Imaging agents useful for identifying AD pathology

The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry

The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography. 

Nitro-imidazole hypoxia imaging agent

Disclosed herein are novel radiolabeled nucleosides and methods for detecting cellular proliferation in a mammal, the method comprising administrating an effective amount of a radiolabeled nucleoside; the method comprising: a) administering to the mammal a diagnostically effective amount of the nucleoside to the mammal; b) allowing the nucleoside to distribute into the effective tissue; and c) imaging the tissue, wherein an increase in binding of the compound to tissue compared to a normal control level of binding indicates that the mammal is suffering from a disease involving cellular proliferation.

Nucleoside based proliferation imaging markers

Nitro-imidazole hypoxia imaging agents

The present application is directed to radiolabeled cyclic polypeptides, pharmaceutical compositions comprising radiolabeled cyclic polypeptides, and methods of using the radiolabeled cyclic polypeptides. Such polypeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins

The invention is a method and related precursor for preparingF-FLT. The precursor has a butoxycarbonyl protecting group at the 5'-position that results in low amounts of chromophoric byproducts being formed during deprotection. The method for preparingF-FLT is efficient and makes the final purification step less complicated.

Method for preparing radiolabeled thymidine having low chromophoric byproducts

The invention relates to a method for preparing F-Dopa andF-Dopa and intermediates that are useful in the method. The invention is a method that synthesizes F-Dopa andF-Dopa in good yield with high enantiopurity without the need for further transformations. The method includes the step of reacting a benzaldehyde derivative with a phosphonic acid derivative to produces an olefin intermediate that can be asymmetrically hydrogenated to produce the desired enantiomer.

Method for making fluorine labeled L-Dopa

Growing community of inventors

Hermosa Beach, CA, United States of America

Henry Clifton Padgett